Changes of hemostasis, endogenous fibrinolysis, platelet activation and endothelins after percutaneous transluminal coronary angioplasty in patients with stable angina

Journal of the American College of Cardiology

Volumn 34, Issue 2, 1999, Pages 486-493

  Borries, Markus ^a   Heins, Michael ^b   Fischer, Yuriko ^a   Stiegler, Hugo ^a   Peters, Ansgar ^a   Reinauer, Hans ^b   Schoebel, Frank C ^c   Strauer, Bodo E ^a   Leschke, Matthias ^a  

^a Pneumologie AngiologieHeinrich H   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ANGINA PECTORIS; ANTICOAGULATION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY OBSTRUCTION; FEMALE; FIBRINOLYSIS; HEMOSTASIS; HUMAN; MALE; PRIORITY JOURNAL; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION INHIBITION; TRANSLUMINAL CORONARY ANGIOPLASTY;

AGED; ANGINA PECTORIS; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTICOAGULANTS; ANTITHROMBIN III; BETA-THROMBOGLOBULIN; CORONARY ANGIOGRAPHY; ENDOTHELINS; FIBRINOGEN; FIBRINOLYSIS; HEMOSTASIS; HEPARIN; HUMANS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PEPTIDE HYDROLASES; PLATELET ACTIVATION; PROTHROMBIN; RECURRENCE; TREATMENT FAILURE;

EID: 0032749077     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(99)00229-6     Document Type: Article

References (35)

1. Detre K., Holubkov R., Kelsey S., et al. Percutaneous transluminal coronary angioplasty in 1985-1986 and 1977-1981. The National Heart, Lung, and Blood Institute Registry. N Engl J Med. 318:1988;265-270.
2. Landau C., Lange R.A., Hillis L.D. Percutaneous transluminal coronary angioplasty. N Engl J Med. 330:1994;981-993.
3. denHeijer P., van Dijk R., Hillege H.L., Pentinga M.L., Serruys P.W., Lie K.I. Serial angioscopic and angiographic observations during the first hour after successful coronary angioplasty a preamble to a multicenter trial addressing angioscopic markers of restenosis . Am Heart J. 128:1994;656-663.
4. Lincoff A.M., Popma J.J., Ellis S.G., Hacker J.A., Topol E.J. Abrupt vessel closure complicating coronary angioplasty clinical, angiographic and therapeutic profile . J Am Coll Cardiol. 19:1992;926-935.
5. Heras M., Chesebro J.H., Penny W.J., et al. Importance of adequate heparin dose in arterial angioplasty in a porcine model. Circulation. 78:1988;654-660.
6. Mabin T.A., Holmes D.R. Jr, Smith H.C., et al. Intracoronary thrombus role in coronary occlusion complicating percutaneous transluminal coronary angioplasty . J Am Coll Cardiol. 5:1985;198-202.
7. Fischell T.A., Derby G., Tse T.M., Stadius M.L. Coronary artery vasoconstriction routinely occurs after percutaneous transluminal coronary angioplasty. A quantitative arteriographic analysis. Circulation. 78:1988;1323-1334.
8. Keber D. On the use of different correction factors for hemoconcentration [letter]. Thromb Haemost. 49:1983;245.
9. Faxon D.P., Weber V.J., Haudenschild C., Gottsmann S.B., McGovern W.A., Ryan T.J. Acute effects of transluminal angioplasty in three experimental models of atherosclerosis. Arteriosclerosis. 2:1982;125-133.
10. Farb A., Virmani R., Atkinson J.B., Kolodgie F.D. Plaque morphology and pathologic changes in arteries from patients dying after coronary balloon angioplasty. J Am Coll Cardiol. 16:1990;1421-1429.
11. Soward A.L., Essed C.E., Serruys P.W. Coronary arterial findings after accidental death immediately after successful percutaneous transluminal coronary angioplasty. Am J Cardiol. 56:1985;794-795.
12. Waxman S., Sassower M.A., Mittleman M.A., et al. Angioscopic predictors of early adverse outcome after coronary angioplasty in patients with unstable angina and non-Q-wave myocardial infarction. Circulation. 93:1996;2106-2113.
13. Fernandez Ortiz A., Badimon J.J., Falk E., et al. Characterization of the relative thrombogenicity of atherosclerotic plaque components implications for consequences of plaque rupture . J Am Coll Cardiol. 23:1994;1562-1569.
14. Marmur J.D., Merlini P.A., Sharma S.K., et al. Thrombin generation in human coronary arteries after percutaneous tranluminal balloon angioplasty. J Am Coll Cardiol. 24:1994;1484-1491.
15. Schwartz L., Bourassa M.G., Lesperance J., et al. Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty. N Engl J Med. 318:1988;1714-1719.
16. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation. N Engl J Med. 330:1994;956-961.
17. Lane D.A., Pejler G., Flynn A.M., Thompson E.A., Lindahl U. Neutralization of heparin-related saccharides by histidine-rich glycoprotein and platelet factor 4. J Biol Chem. 261:1986;3980-3986.
18. Narins C.R., Hillegass W.B. Jr, Nelson C.L., et al. Relation between activated clotting time during angioplasty and abrupt closure. Circulation. 93:1996;667-671.
19. Kunert M., Sorgenicht R., Scheuble L., et al. Value of activated blood coagulation time in monitoring anticoagulation during coronary angioplasty. Z Kardiol. 85:1996;118-124.
20. Heintzen M.P., Motz W., Leschke M., et al. Acute coronary artery occlusion after elective percutaneous transluminal coronary angioplasty. Incidence and therapy in 5,000 consecutive patients. Dtsch Med Wochenschr. 119:1994;1023-1028.
21. Ernst E. Plasma fibrinogen - an independent cardiovascular risk factor. J Intern Med. 227:1990;365-372.
22. Heinrich J., Balleisen L., Schulte H., Assmann G., van de Loo J. Fibrinogen and factor VII in the prediction of coronary risk. Results from the PROCAM study in healthy men. Arterioscler Thromb. 14:1994;54-59.
23. Yarnell J.W., Baker I.A., Sweetnam P.M., et al. Fibrinogen, viscosity, and white blood cell count are major risk factors for ischemic heart disease. The Caerphilly and Speedwell collaborative heart disease studies. Circulation. 83:1991;836-844.
24. Eliasson M., Ervin P.E., Lundblad D., Asplund K., Rånby M. Influence of gender, age and sampling time on plasma fibrinolytic variables and fibrinogen. Fibrinolysis. 7:1993;316-323.
25. Hamsten A., de Faire U., Walldius G., et al. Plasminogen activator inhibitor in plasma risk factor for recurrent myocardial infarction . Lancet. 2:1987;3-9.
26. Juhan Vague I., Pyke S.D., Alessi M.C., Jespersen J., Haverkate F., Thompson S.G. Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. ECAT Study Group. European Concerted Action on Thrombosis and Disabilities. Circulation. 94:1996;2057-2063.
27. Yanagisawa M., Kurihara H., Kimura S., et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 332:1988;411-415.
28. Zeiher A.M., Goebel H., Schachinger V., Ihling C. Tissue endothelin-1 immunoreactivity in the active coronary atherosclerotic plaque. A clue to the mechanism of increased vasoreactivity of the culprit lesion in unstable angina. Circulation. 91:1995;941-947.
29. Levin E.R. Endothelins. N Engl J Med. 333:1995;356-363.
30. Luscher T.F. Endothelium-derived relaxing and contracting factors potential role in coronary artery disease . Eur Heart J. 10:1989;847-857.
31. Borries M., Heins M., Fischer Y., et al. Endothelin and big endothelin in coronary heart disease and acute coronary syndromes. Z Kardiol. 85:1996;761-767.
32. Koller J., Mair P., Wieser C., Pomaroli A., Puschendorf B., Herold M. Endothelin and big endothelin concentrations in injured patients [letter]. N Engl J Med. 325:1991;1518.
33. Kourembanas S., Marsden P.A., McQuillan L.P., Faller D.V. Hypoxia induces endothelin gene expression and secretion in cultured human endothelium. J Clin Invest. 88:1991;1054-1057.
34. Schini V.B., Hendrickson H., Heublein D.M., Burnett J.C. Jr, Vanhoutte P.M. Thrombin enhances the release of endothelin from cultured porcine aortic endothelial cells. Eur J Pharmacol. 165:1989;333-334.
35. Omland T., Lie R.T., Aakvaag A., Aarsland T., Dickstein K. Plasma endothelin determination as a prognostic indicator of 1-year mortality after acute myocardial infarction. Circulation. 89:1994;1573-1579.